Effect of ospemifene on vaginal microbiome in postmenopausal women with vulvovaginal atrophy.
Journal
Menopause (New York, N.Y.)
ISSN: 1530-0374
Titre abrégé: Menopause
Pays: United States
ID NLM: 9433353
Informations de publication
Date de publication:
01 04 2023
01 04 2023
Historique:
medline:
28
3
2023
pubmed:
3
2
2023
entrez:
2
2
2023
Statut:
ppublish
Résumé
This study aimed (i) to compare the vaginal microbiome profiles of women suffering from vulvovaginal atrophy with that of healthy postmenopausal women and to (ii) assess the effect of ospemifene and systemic hormone treatment on the composition of the vaginal microbiome. Sixty-seven postmenopausal women attending the Gynecology Clinic of Azienda Ospedaliero-Universitaria of Bologna (Italy) were enrolled. Of them, 39 received a diagnosis of atrophy and 28 were considered healthy controls. In the group of atrophic women, 20 were prescribed ospemifene and 19 received hormone treatment. The vaginal health index was calculated, and a vaginal swab was collected for the assessment of vaginal maturation index and the analysis of vaginal microbiome through 16S rRNA gene sequencing. Clinical/microbiological analyses were repeated after 3 months of treatment. The vaginal microbiome of atrophic women was characterized by a significant reduction of Lactobacillus ( P = 0.002) and an increase of Streptococcus ( P = 0.008) and Sneathia ( P = 0.02). A positive correlation between vaginal health index/vaginal maturation index and Lactobacillus abundance was found ( P = 0.002 and P = 0.035, respectively). Both therapeutic approaches effectively improved vaginal indices. Systemic hormone treatment induced changes in minority bacterial groups of the vaginal microbiome, whereas ospemifene was able to eliminate specific bacterial taxa, such as Staphylococcus ( P = 0.04) and Clostridium ( P = 0.01). Both treatments induced a trend in the increase of bifidobacteria. The vaginal microbiome of atrophic women differs significantly from that of healthy postmenopausal women. Ospemifene may lead to a condition of vaginal health, likely characterized by the reduction of "potentially harmful" bacteria.
Identifiants
pubmed: 36727789
doi: 10.1097/GME.0000000000002150
pii: 00042192-202304000-00003
doi:
Substances chimiques
Ospemifene
B0P231ILBK
Selective Estrogen Receptor Modulators
0
RNA, Ribosomal, 16S
0
Tamoxifen
094ZI81Y45
Hormones
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
361-369Informations de copyright
Copyright © 2023 by The North American Menopause Society.
Déclaration de conflit d'intérêts
Financial disclosure/conflicts of interest: M.C.M. had past financial relationships (lecturer, member of advisory boards, and/or consultant) with Shionogi Limited, Teramex, Organon, Italfarmaco, MDS Italia, and Bayer; M.B. had past financial relationships (consultant) with Shionogi Limited. The rest of the authors declare no conflict of interest.
Références
Marino JM. Genitourinary syndrome of menopause. J Midwifery Womens Health 2021;66:729–739. doi: 10.1111/jmwh.13277
doi: 10.1111/jmwh.13277
Alvisi S, Baldassarre M, Gava G, et al. Knowledge of genito-urinary syndrome of menopause among Italian gynecologists: the DIADEM survey. Maturitas 2021;143:89–95. doi: 10.1016/j.maturitas.2020.09.011
doi: 10.1016/j.maturitas.2020.09.011
Palacios S, Castelo-Branco C, Currie H, et al. Update on management of genitourinary syndrome of menopause: a practical guide. Maturitas 2015;82:308–313. doi: 10.1016/j.maturitas.2015.07.020
doi: 10.1016/j.maturitas.2015.07.020
Palma F, Volpe A, Villa P, Cagnacci A; Writing group of AGATA study. Vaginal atrophy of women in postmenopause. Results from a multicentric observational study: The AGATA study. Maturitas 2016;83:40–44. doi: 10.1016/j.maturitas.2015.09.001
doi: 10.1016/j.maturitas.2015.09.001
The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause 2020;27:976–992. doi: 10.1097/GME.0000000000001609
doi: 10.1097/GME.0000000000001609
Brotman RM, Shardell MD, Gajer P, et al. Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy. Menopause 2014;21:450–458. doi: 10.1097/GME.0b013e3182a4690b
doi: 10.1097/GME.0b013e3182a4690b
Shen J, Song N, Williams CJ, et al. Effects of low dose estrogen therapy on the vaginal microbiomes of women with atrophic vaginitis. Sci Rep 2016;6:24380. doi: 10.1038/srep24380
doi: 10.1038/srep24380
Foschi C, Alvisi S, Baldassarre M, et al. Vaginal metabolites in postmenopausal women with or without vulvo-vaginal atrophy at baseline and after ospemifeme and systemic hormone treatment. Maturitas 2022;159:7–14. doi: 10.1016/j.maturitas.2021.12.007
doi: 10.1016/j.maturitas.2021.12.007
Tinelli A, Malvasi A, Rahimi S, et al. Age-related pelvic floor modifications and prolapse risk factors in postmenopausal women. Menopause 2010;17:204–212. doi: 10.1097/gme.0b013e3181b0c2ae
doi: 10.1097/gme.0b013e3181b0c2ae
Bachmann G. Urogenital ageing: an old problem newly recognized. Maturitas 1995;22(Suppl):S1–S5. doi: 10.1016/0378-5122(95)00956-6
doi: 10.1016/0378-5122(95)00956-6
Hess R, Austin RM, Dillon S, Chang CCH, Ness RB. Vaginal maturation index self-sample collection in mid-life women: acceptability and correlation with physician-collected samples. Menopause 2008;15:726–729. doi: 10.1097/gme.0b013e31816c5541
doi: 10.1097/gme.0b013e31816c5541
Cagnacci A, Gallo M, Gambacciani M, Lello S. Joint recommendations for the diagnosis and treatment of vulvo-vaginal atrophy in women in the peri- and post-menopausal phases from the Società Italiana per la Menopausa (SIM) and the Società Italiana della Terza Età (SIGiTE). Minerva Ginecol 2019;71:345–352. doi: 10.23736/S0026-4784.19.04469-1
doi: 10.23736/S0026-4784.19.04469-1
Severgnini M, Camboni T, Ceccarani C, et al. Distribution of ermB, ermF, tet(W), and tet(M) resistance genes in the vaginal ecosystem of women during pregnancy and puerperium. Pathogens 2021;10:1546. doi: 10.3390/pathogens10121546
doi: 10.3390/pathogens10121546
Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJ, Holmes SP. DADA2: high-resolution sample inference from Illumina amplicon data. Nat Methods 2016;13:581–583. doi: 10.1038/nmeth.3869
doi: 10.1038/nmeth.3869
McMurdie PJ, Holmes S. phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PLoS One 2013;8:e61217. doi: 10.1371/journal.pone.0061217
doi: 10.1371/journal.pone.0061217
Lozupone C, Lladser ME, Knights D, Stombaugh J, Knight R. UniFrac: an effective distance metric for microbial community comparison. ISME J 2011;5:169–172. doi: 10.1038/ismej.2010.133
doi: 10.1038/ismej.2010.133
Wang Q, Garrity GM, Tiedje JM, Cole JR. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol 2007;73:5261–5267. doi: 10.1128/AEM.00062-07
doi: 10.1128/AEM.00062-07
Parks DH, Chuvochina M, Rinke C, Mussig AJ, Chaumeil PA, Hugenholtz P. GTDB: an ongoing census of bacterial and archaeal diversity through a phylogenetically consistent, rank normalized and complete genome-based taxonomy. Nucleic Acids Res 2022;50(D1):D785–D794. doi: 10.1093/nar/gkab776
doi: 10.1093/nar/gkab776
Ceccarani C, Foschi C, Parolin C, et al. Diversity of vaginal microbiome and metabolome during genital infections. Sci Rep 2019;9:14095. doi: 10.1038/s41598-019-50410-x
doi: 10.1038/s41598-019-50410-x
Raimondi S, Candeliere F, Amaretti A, et al. Vaginal and anal microbiome during Chlamydia trachomatis infections. Pathogens 2021;10:1347. doi: 10.3390/pathogens10101347
doi: 10.3390/pathogens10101347
Hummelen R, Macklaim JM, Bisanz JE, et al. Vaginal microbiome and epithelial gene array in post-menopausal women with moderate to severe dryness. PLoS One 2011;6:e26602. doi: 10.1371/journal.pone.0026602
doi: 10.1371/journal.pone.0026602
Mitchell CM, Ma N, Mitchell AJ, et al. Association between postmenopausal vulvovaginal discomfort, vaginal microbiota, and mucosal inflammation. Am J Obstet Gynecol 2021;225:159.e1–159.e15. doi: 10.1016/j.ajog.2021.02.034
doi: 10.1016/j.ajog.2021.02.034
Petricevic L, Unger FM, Viernstein H, Kiss H. Randomized, double-blind, placebo-controlled study of oral lactobacilli to improve the vaginal flora of postmenopausal women. Eur J Obstet Gynecol Reprod Biol 2008;141:54–57. doi: 10.1016/j.ejogrb.2008.06.003
doi: 10.1016/j.ejogrb.2008.06.003
Sonthalia S, Aggarwal P, Das S, Sharma P, Sharma R, Singh S. Aerobic vaginitis—an underdiagnosed cause of vaginal discharge—narrative review. Int J STD AIDS 2020;31:1018–1027. doi: 10.1177/0956462420913435
doi: 10.1177/0956462420913435
Zhou FY, Zhou Q, Zhu ZY, Hua KQ, Chen LM, Ding JX. Types and viral load of human papillomavirus, and vaginal microbiota in vaginal intraepithelial neoplasia: a cross-sectional study. Ann Transl Med 2020;8:1408. doi: 10.21037/atm-20-622
doi: 10.21037/atm-20-622
Freitas AC, Hill JE. Quantification, isolation and characterization of Bifidobacterium from the vaginal microbiomes of reproductive aged women. Anaerobe 2017;47:145–156. doi: 10.1016/j.anaerobe.2017.05.012
doi: 10.1016/j.anaerobe.2017.05.012
Ratten LK, Plummer EL, Murray GL, et al. Sex is associated with the persistence of non-optimal vaginal microbiota following treatment for bacterial vaginosis: a prospective cohort study. BJOG 2021;128:756–767. doi: 10.1111/1471-0528.16430
doi: 10.1111/1471-0528.16430